var data={"title":"Gabapentin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gabapentin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6246?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">see &quot;Gabapentin: Drug information&quot;</a> and <a href=\"topic.htm?path=gabapentin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gabapentin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175023\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fanatrex FusePaq;</li>\n      <li>Gralise;</li>\n      <li>Gralise Starter;</li>\n      <li>Neuraptine;</li>\n      <li>Neurontin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50769812\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Neurontin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053083\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053074\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">see &quot;Gabapentin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not exceed 12 hours between doses with 3 times daily dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric: <b>Note:</b> Pediatric doses presented as mg/kg/day and mg/kg/dose; use precaution.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Seizures, partial onset; adjunctive therapy:</b> Oral: Immediate release: <b>Note:</b> If gabapentin is discontinued or if another anticonvulsant is added to therapy, it should be done slowly over a minimum of 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 3 to &lt;12 years: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial: 10 to 15 mg/kg/<b>day</b> divided into 3 doses daily; titrate dose upward over ~3 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Maintenance usual dose: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Children 3 to 4 years: 40 mg/kg/<b>day</b> divided into 3 doses daily; maximum daily dose:  In one long-term study, doses up to 50 mg/kg/<b>day</b> were well-tolerated</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Children 5 to &lt;12 years: 25 to 35 mg/kg/<b>day</b> divided into 3 doses daily; maximum daily dose:  In one long-term study, doses up to 50 mg/kg/<b>day</b> were well-tolerated     </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;12 years and Adolescents: Initial: 300 mg 3 times daily; titrate dose upward if needed; usual maintenance dose: 900 to 1,800 mg/day divided into 3 doses daily; doses up to 2,400 mg/day divided into 3 doses daily are well tolerated long-term; maximum daily dose: Doses up to 3,600 mg/<b>day</b>  have been tolerated in short-term studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Neuropathic pain:</b> Limited data available: Oral: Immediate release: Children and Adolescents: Initial: 5 mg/kg/dose up to 300 mg at bedtime; day 2: Increase to 5 mg/kg/dose twice daily (up to 300 mg twice daily); day 3: Increase to 5 mg/kg/dose 3 times daily (up to 300 mg 3 times daily); further titrate with dosage increases (not frequency) to effect; American Pain Society (APS) recommends a lower initial dose of 2 mg/kg/<b>day</b> which may be considered if concurrent analgesics are also sedating; usual dosage range: 8 to 35 mg/kg/<b>day</b> divided into 3 doses daily (APS, 2008; Galloway, 2000); maximum daily dose: 3,600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Seizures, partial onset:</b> Oral: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Initial: 300 mg 3 times daily, if necessary the dose may be gradually increased up to 1,800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maintenance: 900 to 1,800 mg/<b>day</b> administered in 3 divided doses; doses of up to 2,400 mg/<b>day</b> have been tolerated in long-term clinical studies; doses up to 3,600 mg/<b>day</b> have been tolerated in short-term studies </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Note:</b> If gabapentin is discontinued or if another anticonvulsant is added to therapy, it should be done slowly over a minimum of 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Post-herpetic neuralgia:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immediate release: Day 1: 300 mg once; Day 2: 300 mg twice daily; Day 3: 300 mg 3 times daily; titrate dose as needed for pain relief (range: 1,800 to 3,600 mg/<b>day</b> in divided doses; doses &gt;1,800 mg/<b>day</b> do not generally show greater benefit) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release (Gralise): Day 1: 300 mg once, Day 2: 600 mg once, Days 3 to 6: 900 mg once daily, Days 7 to 10: 1,200 mg once daily, Days 11 to 14: 1,500 mg once daily, Days &ge;15: 1,800 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &lt;12 years: There are no dosing adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;12 years, Adolescents, and Adults: See table. </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Gabapentin Dosing Adjustments in Renal Impairment</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Creatinine Clearance</p>\n            <p style=\"text-indent:0em;\">(mL/min)</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Daily Dose Range</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th>\n          <th colspan=\"5\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dosage Regimens</p>\n            <p style=\"text-indent:0em;\">(Maintenance Doses)</p>\n            <p style=\"text-indent:0em;\">(mg)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"7\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>CrCl &lt;15 mL/minute: Reduce daily dose in proportion to creatinine clearance.</p></td></tr>\n        <tr>\n          <td colspan=\"7\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Supplemental dose should be administered after each 4 hours of hemodialysis (patients on hemodialysis should also receive maintenance doses based on renal function as listed in the upper portion of the table).</p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">900 to 3,600</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 </p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400 </p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">600 </p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">800 </p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1200 tid</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;30 to 59</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400 to 1,400</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 twice daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 twice daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400 twice daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 twice daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">700 twice daily</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;15 to 29</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 to 700</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">700 daily</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15<sup>1</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100 to 300</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 daily</p></td></tr>\n        <tr>\n          <td colspan=\"2\" rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Hemodialysis<sup>2</sup></b></p></td>\n          <td colspan=\"5\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Posthemodialysis Supplemental Dose</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">350 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Extended release (Gralise): <b>Note:</b> Follow initial dose titration schedule if treatment-naive.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: 1,800 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;30 to 59 mL/minute: 600 to 1,800 mg once daily; dependent on tolerability and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, adjustment not necessary since gabapentin is not hepatically metabolized.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174997\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neurontin: 100 mg, 300 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 300 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuraptine: 10% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gralise Starter: 300 &amp; 600 mg (78 ea) [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neurontin: 250 mg/5 mL (470 mL) [strawberry anise flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/5 mL (5 mL, 470 mL, 473 mL); 300 mg/6 mL (6 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fanatrex FusePaq: 25 mg/mL (420 mL) [contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gralise: 300 mg [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gralise: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neurontin: 600 mg, 800 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 600 mg, 800 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174981\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28799619\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">see &quot;Gabapentin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gralise is the extended release formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fanatrex FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuraptine cream is compounded from a kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10916634\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neurontin: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68rYi5XW2D09twyH6QySiWIw==&amp;TOPIC_ID=13330\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gralise: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM245196.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68miQs1AlzdgDYd0nnv+jv0A==&amp;TOPIC_ID=13330\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM245196.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053088\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Capsule, tablet, oral solution: May consider administration of first dose on first day at bedtime to avoid somnolence and dizziness. May be administered without regard to meals; administration with meals may decrease adverse GI effects. Dose may be administered as combination of dosage forms; do not administer within 2 hours of magnesium- or aluminum-containing antacids. When given 3 times daily, the maximum time between doses should not exceed 12 hours. Capsule should be administered with plenty of water to ensure complete swallowing. Although the manufacturer recommends swallowing capsules whole, some centers have opened the capsules and mixed the contents in drinks (eg, orange juice) or food (eg, applesauce) when necessary ( Gidal 1998; Khurana 1996). The 600 mg and 800 mg tablets are scored and may be split if a half-tablet is needed; manufacturer recommends that half tablets not used within 28 days of breaking the scored tablets should be discarded. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release (Gralise): Tablet: Take once daily with evening meal. Swallow whole; do not chew, crush, or split. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175017\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules and tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Use scored 600 or 800 mg tablets that are broken in half within 28 days of breaking the tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053087\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct for treatment of partial seizures with or without secondary generalized seizures (Neurontin: FDA approved in ages &ge;3 years  and adults); management of post-herpetic neuralgia (Gralise, Neurontin: FDA approved in adults); has also been used as adjunct in the treatment of neuropathic pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175068\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Neurontin may be confused with Motrin, Neoral, nitrofurantoin, Noroxin [DSC],  Zarontin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175066\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, abnormality in thinking, amnesia, ataxia, depression, dizziness (more common in adults), drowsiness (more common in adults), emotional lability (children), fatigue (more common in adults), headache (children and adolescents), hostility (children), hyperesthesia, hyperkinesia (children), lethargy, nervousness, pain, tremor, twitching, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, constipation, dental disease, diarrhea, dry throat, dyspepsia, flatulence, increased appetite, nausea and vomiting (more common in children), xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased white blood cell count, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, viral infection (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, bone fracture, dysarthria, limb pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Amblyopia, blurred vision, conjunctivitis, diplopia, nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis (children), cough, nasopharyngitis, pharyngitis, respiratory tract infection (children), rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function, acute renal failure, agitation, altered serum glucose, anaphylaxis, anemia, angina pectoris, angioedema, aphasia, aspiration pneumonia, blindness, blood coagulation disorder, bradycardia, brain disease, breast hypertrophy, bronchospasm, cardiac arrhythmia (various), cerebrovascular accident, change in libido, cholestatic hepatitis, CNS neoplasm, colitis, confusion, Cushingoid appearance, DRESS syndrome, drug abuse, drug dependence, dyspnea, ejaculatory disorder, erythema multiforme, facial paralysis, falling, fecal incontinence, fulminant hepatitis, gastroenteritis, glaucoma, glycosuria, gynecomastia, hearing loss, heart block, hematemesis, hematuria, hemiplegia, hemorrhage, hepatitis, hepatomegaly, herpes zoster, hyperlipidemia, hypersensitivity reaction, hypertension, hyperthyroidism, hyperventilation, hypoglycemia, hyponatremia, hypotension, hypothyroidism, hypoventilation, increased creatine phosphokinase, increased liver enzymes, increased serum creatinine, jaundice, joint swelling, leukocytosis, loss of consciousness, lymphadenopathy, lymphocytosis, memory impairment, meningism, migraine, movement disorder, myocardial infarction, myoclonus (local), nephrolithiasis, nephrosis, nerve palsy, non-Hodgkin lymphoma, ovarian failure, palpitations, pancreatitis, paresthesia, peptic ulcer, pericardial effusion, pericardial rub, pericarditis, peripheral vascular disease, pneumonia, psychosis, pulmonary edema, pulmonary thromboembolism, purpura, retinopathy, rhabdomyolysis, seasonal allergy, sexual disorder, skin necrosis, status epilepticus, Stevens-Johnson syndrome, subdural hematoma, suicidal ideation, suicidal tendencies, syncope, tachycardia, thrombocytopenia, thrombophlebitis, tumor growth, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175005\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gabapentin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174985\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/angioedema: May occur after the first dose or at any time during treatment. Discontinue therapy and seek immediate medical care if signs or symptoms of anaphylaxis or angioedema occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression including somnolence and dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity: Potentially serious, sometimes fatal multiorgan hypersensitivity (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]) has been reported with some antiepileptic drugs, including gabapentin. Monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, cardiac, and/or hematologic systems; fever, rash, and eosinophilia may also be present. Discontinue immediately if suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric effects: Use in pediatric patients with epilepsy has been associated with the occurrence of CNS adverse effects of mild to moderate intensity. The most significant include emotional lability, hostility (eg, aggressive behaviors), changes in behavior and thinking (eg, concentration problems and changes in school performance), and hyperkinesia (primarily restlessness and hyperactivity).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; dose adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: The safety and efficacy of the extended release formulation has not been studied in patients with epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Immediate release and extended release products are not interchangeable with each other or with gabapentin enacarbil due to differences in formulations, indications, and pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumorigenic potential: Male rat studies demonstrated an association with pancreatic adenocarcinoma (clinical implication in humans is unknown).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. The extended release formulation should be withdrawn over &ge;1 week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25881756\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Neuropsychiatric adverse events, such as emotional lability (eg, behavioral problems), hostility, aggressive behaviors, thought disorders (eg, problems with concentration and school performance), and hyperkinesia (eg, hyperactivity and restlessness), have been reported in clinical trials of pediatric patients ages 3 to 12 years. Most of these pediatric neuropsychiatric adverse events are mild to moderate in terms of intensity but discontinuation of gabapentin may be required; children with mental retardation and attention-deficit disorders may be at increased risk for behavioral side effects (Lee 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299373\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174990\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13330&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after oral magnesium salts administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Systemic): Gabapentin may enhance the CNS depressant effect of Morphine (Systemic). Morphine (Systemic) may increase the serum concentration of Gabapentin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175018\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Tablet, solution (immediate release): No significant effect on rate or extent of absorption; extended release tablet: Increases rate and extent of absorption. Management: Administer immediate release products without regard to food. Administer extended release with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174993\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175008\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Gabapentin crosses the placenta. In a small study (n=6), the umbilical/maternal plasma concentration ratio was ~1.74. Neonatal concentrations declined quickly after delivery and at 24 hours of life were ~27% of the cord blood concentrations at birth (gabapentin neonatal half-life ~14 hours) (Ohman 2005). Pregnancy registry outcome data following maternal use of gabapentin during pregnancy is limited (Holmes 2012). Folic acid supplementation is recommended prior to and during pregnancy in women using gabapentin (Borgelt 2016; Picchietti 2015). Gabapentin is used for the treatment of restless leg syndrome; however, current guidelines note there is insufficient evidence to recommend its use in pregnant women for this indication (Picchietti 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Patients exposed to gabapentin during pregnancy are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053082\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Seizure frequency and duration; renal function; weight; behavior in children; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053086\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Routine monitoring of drug levels is not required; a specific target serum concentration range for antiseizure response has not been established (Lindberger 2003); a minimum effective serum concentration may be 2 mcg/mL (Krasowski 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174984\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gabapentin is structurally related to GABA. However, it does not bind to GABA<sub>A</sub> or GABA<sub>B</sub> receptors, and it does not appear to influence synthesis or uptake of GABA. High affinity gabapentin binding sites have been located throughout the brain; these sites correspond to the presence of voltage-gated calcium channels specifically possessing the alpha-2-delta-1 subunit. This channel appears to be located presynaptically, and may modulate the release of excitatory neurotransmitters which participate in epileptogenesis and nociception.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175004\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Variable, from proximal small bowel by L-amino transport system; saturable process; dose-dependent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 58 &plusmn; 6 L; CSF concentrations are ~20% of plasma concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;3%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Inversely proportional to dose due to saturable absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">900 mg/day: 60%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1,200 mg/day: 47%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2,400 mg/day: 34%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3,600 mg/day: 33%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4,800 mg/day: 27%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Variable; increased with higher fat content meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 month to Children 12 years: 4.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults, normal: 5 to 7 hours; increased half-life with decreased renal function; anuric adult patients: 132 hours; adults during hemodialysis: 3.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Immediate release: Infants 1 month to Children 12 years: 2 to 3 hours; Adults: 2 to 4 hours; Extended release: 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Proportional to renal function; urine (as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Apparent oral clearance is directly proportional to CrCl: Clearance in infants is highly variable; oral clearance (per kg) in children &lt;5 years of age is higher than in children &ge;5 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175003\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Commercial oral solution is available (50 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 100 mg/mL suspension may be made with tablets (immediate release) and either a 1:1 mixture of Ora-Sweet&reg; (100 mL) and Ora-Plus&reg; (100 mL) or 1:1 mixture of methylcellulose 1% (100 mL) and Simple Syrup N.F. (100 mL). Crush sixty-seven 300 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 200 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 91 days refrigerated (preferred) or 56 days at room temperature.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175007\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Gabapentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $53.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $133.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $159.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Neurontin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $255.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (50): $348.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (50): $404.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Neuraptine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (30 mL): $195.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Misc</b> (Gralise Starter Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 &amp; 600 mg (78): $722.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gabapentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (470 mL): $148.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neurontin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (470 mL): $475.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Fanatrex FusePaq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (420 mL): $490.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Gabapentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $252.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $303.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Gralise Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (90): $834.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (90): $834.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Neurontin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $1,211.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $1,453.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175011\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alpentin (ID);</li>\n      <li>Anatin (LK);</li>\n      <li>Bapex (MX);</li>\n      <li>Barontin (KR);</li>\n      <li>Bineurox (VN);</li>\n      <li>Blugat (MX);</li>\n      <li>Calmpent (PH);</li>\n      <li>Carbatin (TW);</li>\n      <li>Die Li (CN);</li>\n      <li>Dineurin (CL);</li>\n      <li>Dineurol (PY);</li>\n      <li>Engaba (PK);</li>\n      <li>Epiven (ID, MY, PH);</li>\n      <li>Epleptin (ZA);</li>\n      <li>Etoclon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>G-Pentin (TH);</li>\n      <li>Gabadin (PY);</li>\n      <li>Gabagamma (LV);</li>\n      <li>Gabalept (RO);</li>\n      <li>Gabamax (BD);</li>\n      <li>Gabanet (JO, LB, QA);</li>\n      <li>Gabantin (MX);</li>\n      <li>Gabapen (JP);</li>\n      <li>Gabapenin (KR);</li>\n      <li>Gabaran (AU);</li>\n      <li>Gabaron (PH);</li>\n      <li>Gabasant (ID);</li>\n      <li>Gabatin (CH, KR, LK);</li>\n      <li>Gabatine (AU);</li>\n      <li>Gabator (PH, TZ, ZW);</li>\n      <li>Gabatrex (QA);</li>\n      <li>Gabavex (PH);</li>\n      <li>Gabenil (HK);</li>\n      <li>Gabictal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gabin (IE);</li>\n      <li>Gabix (PH);</li>\n      <li>Gabon (BD);</li>\n      <li>Gabutin (TH);</li>\n      <li>Gantin (AU);</li>\n      <li>Gapatin (TW);</li>\n      <li>Gapridol (MX);</li>\n      <li>Gaty (TW);</li>\n      <li>Gonnaz (PH);</li>\n      <li>Gordius (LV);</li>\n      <li>Habamaks (UA);</li>\n      <li>Hrymodyn (UA);</li>\n      <li>Meditan (UA);</li>\n      <li>Mirgy (VN);</li>\n      <li>Nepsy (BD);</li>\n      <li>Neuleptol (KR);</li>\n      <li>Neupentin (LK);</li>\n      <li>Neuran (HK, MY);</li>\n      <li>Neuril (DK);</li>\n      <li>Neurontin (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CN, CO, CY, CZ, DE, EC, EE, EG, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PH, PL, PR, PT, QA, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, UY, VE, VN, YE, ZA);</li>\n      <li>Neuropen (BD);</li>\n      <li>Neurostil (IE);</li>\n      <li>New-GABA (KR);</li>\n      <li>Neyralhin (UA);</li>\n      <li>Nopatic (MX);</li>\n      <li>Nupentin (AU, NZ, SG);</li>\n      <li>Nurona (JO, LB);</li>\n      <li>Opipentin (ID);</li>\n      <li>Pendine (AU);</li>\n      <li>Pengatine (KR);</li>\n      <li>Penral (LK);</li>\n      <li>Reinin (PH);</li>\n      <li>Remaltin (TW);</li>\n      <li>Rontin (TH);</li>\n      <li>Sipentin (ID);</li>\n      <li>Tebantin (VN);</li>\n      <li>Volar (JO, LB);</li>\n      <li>Vultin (HK, TH);</li>\n      <li>Vultin 600 (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/9099467/pubmed\" target=\"_blank\" id=\"9099467\">9099467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrews CO and Fischer JH, &ldquo;Gabapentin: A New Agent for the Management of Epilepsy,&rdquo; <i>Ann Pharmacother</i>, 1994, 28(10):1188-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/7841578/pubmed\" target=\"_blank\" id=\"7841578\">7841578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borgelt LM, Hart FM, Bainbridge JL. Epilepsy during pregnancy: focus on management strategies. <i>Int J Womens Health</i>. 2016;8:505-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/27703396/pubmed\" target=\"_blank\" id=\"27703396\">27703396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26131874\"></a>Davanzo R, Dal Bo S, Bua J, Copertino M, Zanelli E, Matarazzo L. Antiepileptic drugs and breastfeeding. <i>Ital J Pediatr</i>. 2013;39:50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/26131874/pubmed\" target=\"_blank\" id=\"26131874\">26131874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galloway KS and Yaster M, &ldquo;Pain and Symptom Control in Terminally Ill Children,&rdquo; <i>Pediatr Clin North Am</i>, 2000, 47(3):711-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/10835999/pubmed\" target=\"_blank\" id=\"10835999\">10835999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gidal BE, Maly MM, Kowalski JW, Rutecki PA, Pitterle ME, Cook DE. Gabapentin absorption: effect of mixing with foods of varying macronutrient composition.<i> Ann Pharmacother</i>. 1998;32(4):405-409.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/9562133 /pubmed\" target=\"_blank\" id=\"9562133 \">9562133 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes LB and Hernandez-Diaz S, &quot;Newer Anticonvulsants: Lamotrigine, Topiramate, and Gabapentin,&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(8):599-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/22730257/pubmed\" target=\"_blank\" id=\"22730257\">22730257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khurana DS, Riviello J, Helmers S, et al, &ldquo;Efficacy of Gabapentin Therapy in Children With Refractory Partial Seizures,&rdquo; <i>J Pediatr</i>, 1996, 128(6):829-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/8648543/pubmed\" target=\"_blank\" id=\"8648543\">8648543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krasowski MD. Therapeutic drug monitoring of the newer anti-epilepsy medications. <i>Pharmaceuticals (Basel)</i>. 2010;3(6):1909-1935.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/20640233 /pubmed\" target=\"_blank\" id=\"20640233 \">20640233 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee DO, Steingard RJ, Cesena M, et al, &ldquo;Behavioral Side Effects of Gabapentin in Children,&rdquo; <i>Epilepsia</i>, 1996, 37(1):87-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/8603631 /pubmed\" target=\"_blank\" id=\"8603631 \">8603631 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. <i>Ther Drug Monit</i>. 2003;25(4):457-462.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/12883229 /pubmed\" target=\"_blank\" id=\"12883229 \">12883229 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neurontin (gabapentin) [prescribing information]. New York, NY: Parke-Davis; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohman I, Vitols S, and Tomson T, &quot;Pharmacokinetics of Gabapentin During Delivery, in the Neonatal Period, and Lactation: Does a Fetal Accumulation Occur During Pregnancy?&quot; <i>Epilepsia</i>, 2005, 46(10):1621-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/16190933/pubmed\" target=\"_blank\" id=\"16190933\">16190933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25553600\"></a>Picchietti DL, Hensley JG, Bainbridge JL, et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. <i>Sleep Med Rev</i>. 2015;22:64-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/25553600/pubmed\" target=\"_blank\" id=\"25553600\">25553600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pressler KL, Jabbour JT, Rose DF, et al, &ldquo;Gabapentin and Aggression in Pediatric Patients: A Review of the Literature,&rdquo; <i>Journal of Pediatric Pharmacy Practice</i>, 1998, 3(2):100-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veiby G, Bj&oslash;rk M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. <i>Seizure</i>. 2015;28:57-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-pediatric-drug-information/abstract-text/25837494/pubmed\" target=\"_blank\" id=\"25837494\">25837494</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13330 Version 277.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F175023\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50769812\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053083\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053074\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F174997\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F174981\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F28799619\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10916634\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053088\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F175017\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053087\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F175068\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F175066\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F175005\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F174985\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25881756\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299373\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F174990\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F175018\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F174993\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F175008\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053082\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1053086\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F174984\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F175004\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F175003\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F175007\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F175011\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13330|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">Gabapentin: Drug information</a></li><li><a href=\"topic.htm?path=gabapentin-patient-drug-information\" class=\"drug drug_patient\">Gabapentin: Patient drug information</a></li></ul></div></div>","javascript":null}